Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Revenue (2023 - 2025)

CG Oncology (CGON) has disclosed Revenue for 3 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 409.21% year-over-year to $2.3 million, compared with a TTM value of $4.0 million through Dec 2025, up 254.7%, and an annual FY2025 reading of $4.0 million, up 254.7% over the prior year.
  • Revenue was $2.3 million for Q4 2025 at CG Oncology, up from $1.7 million in the prior quarter.
  • Across five years, Revenue topped out at $2.3 million in Q4 2025 and bottomed at $1000.0 in Q4 2023.
  • Average Revenue over 3 years is $538300.0, with a median of $152500.0 recorded in 2023.
  • The sharpest move saw Revenue surged 45500.0% in 2024, then plummeted 90.17% in 2025.
  • Year by year, Revenue stood at $1000.0 in 2023, then soared by 45500.0% to $456000.0 in 2024, then soared by 409.21% to $2.3 million in 2025.
  • Business Quant data shows Revenue for CGON at $2.3 million in Q4 2025, $1.7 million in Q3 2025, and $52000.0 in Q1 2025.